PD-L1 IHC 28-8 pharmDx training
Learn how to evaluate PD-L1 expression in patients with non-squamous NSCLC for OPDIVO® (nivolumab).
Leading the way
in PD-L1 testing
Introducing the first and only FDA-approved test to assess patients with NSCLC for KEYTRUDA® (pembrolizumab).
Results you can trust
The first and only FDA-approved and
CE-IVD marked PD-L1 test for use in
non-squamous NSCLC for OPDIVO® (nivolumab).
Review of Breast Cancer Diagnosis
In collaboration with leading experts, Agilent publishes a new comprehensive review on breast cancer diagnostic testing.
See our solutions within pathology, next generation sequencing and molecular cancer research.
New Product Catalog Available
The 2016 Pathology Product Catalog is now available.
Events and Congresses
Meet us at congresses and events around the world.